| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) including noncontrolling interests in subsidiaries | 19,697 | 22,091 |
| Depreciation, depletion and amortization | 32,891 | 22,055 |
| Accretion of asset retirement obligation | -1,299 | -867 |
| Compensation expense for share-based awards | 3,751 | 1,876 |
| (gain) loss on foreign currency exchange | 405 | 435 |
| Change in fair value of equity securities | -1,658 | -2,558 |
| Gain on sale of equity securities | 3,512 | 3,512 |
| Unrealized gain on derivatives | 1,495 | 789 |
| Deferred income taxes | 3,609 | 3,646 |
| Accounts receivable | 284 | -3,501 |
| Inventories | -995 | -1,760 |
| Prepaid expenses and other assets | 3,284 | 4,114 |
| Amortization of debt discount and issuance costs | - | 95 |
| Accounts payable and accrued expenses | 5,455 | 2,551 |
| Royalties and contingent legal fees payable | 1,529 | 231 |
| Deferred revenue | 188 | 164 |
| Net cash provided by operating activities | 62,092 | 52,545 |
| Acquisition, net of cash acquired and working capital adjustments (note 3) | -1,230 | -1,230 |
| Patent acquisition | 0 | 0 |
| Purchases of equity securities | 17,368 | 12,543 |
| Sales of equity securities | 15,165 | 15,165 |
| Purchases of loans receivable | 3,364 | - |
| Purchases of property and equipment | 1,401 | 940 |
| Net additions to oil and gas properties | 8,961 | 3,363 |
| Net cash used in investing activities | -14,699 | -451 |
| Repurchase of common stock | 0 | - |
| Contributions from noncontrolling interest | 0 | 0 |
| Borrowings on the benchmark revolving credit facility | 4,000 | 0 |
| Paydown of benchmark revolving credit facility | 12,000 | 8,500 |
| Paydown of deflecto facility | 12,100 | 1,200 |
| Taxes paid related to net share settlement of share-based awards | 670 | 670 |
| Proceeds from exercise of stock options | 30 | 30 |
| Net cash (used in) provided by financing activities | -20,740 | -10,340 |
| Effect of exchange rates on cash and cash equivalents | 1,247 | 1,087 |
| Increase in cash and cash equivalents | 27,900 | 42,841 |
| Cash and cash equivalents at beginning of period | 273,880 | - |
| Cash and cash equivalents at end of period | 301,780 | - |
ACACIA RESEARCH CORP (ACTG)
ACACIA RESEARCH CORP (ACTG)